Bristol Myers Squibb Files 8-K with Financial Updates

TL;DR

BMS filed an 8-K on 3/18/24 detailing notes and CVRs.

AI Summary

Bristol Myers Squibb Company filed an 8-K on March 18, 2024, reporting on "Other Events" and "Financial Statements and Exhibits." The filing includes details about various financial instruments such as Celgene Contingent Value Rights, One750 Notes Due 2035, and One000 Notes Due 2025, all with a reporting date of March 18, 2024.

Why It Matters

This filing provides important updates on Bristol Myers Squibb's financial instruments and exhibits, which can impact investor understanding of the company's financial health and obligations.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial instruments and exhibits, not indicating any immediate operational or financial distress.

Key Players & Entities

• Bristol Myers Squibb Company (company) — Registrant
• March 18, 2024 (date) — Filing Date
• Celgene Contingent Value Rights (financial_instrument) — Mentioned in filing
• One750 Notes Due 2035 (financial_instrument) — Mentioned in filing
• One000 Notes Due 2025 (financial_instrument) — Mentioned in filing

FAQ

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan
• $330.00 — lly converted into the right to receive $330.00 in cash, without interest, and subject

Filing Documents

• ef20024275_8k.htm (8-K) — 36KB
• ef20024275_ex99-1.htm (EX-99.1) — 17KB
• image00001.jpg (GRAPHIC) — 5KB
• 0001140361-24-013726.txt ( ) — 247KB
• bmy-20240318.xsd (EX-101.SCH) — 5KB
• bmy-20240318_def.xml (EX-101.DEF) — 18KB
• bmy-20240318_lab.xml (EX-101.LAB) — 27KB
• bmy-20240318_pre.xml (EX-101.PRE) — 20KB
• ef20024275_8k_htm.xml (XML) — 8KB

01

Item 8.01. Other Events. On March 18, 2024, Bristol-Myers Squibb Company ("BMS") issued a press release announcing the completion of its previously announced acquisition (the "Acquisition") of Karuna Therapeutics, Inc. ("Karuna"). In the Acquisition, each share of Karuna common stock issued and outstanding immediately prior to the effective time of the Acquisition (other than certain excluded shares as described in the agreement and plan of merger entered into among BMS, Karuna and Miramar Merger Sub Inc., a wholly owned subsidiary of BMS) was automatically converted into the right to receive $330.00 in cash, without interest, and subject to any required withholding taxes. A copy of the press release announcing the closing of the Acquisition is filed as Exhibit 99.1 to this report and is incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are included as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Press Release of Bristol-Myers Squibb Company, dated March 18, 2024. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). EXHIBIT INDEX Exhibit No. Description 99.1 Press Release of Bristol-Myers Squibb Company, dated March 18, 2024. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: March 18, 2024 By: /s/ Kimberly M. Jablonski Name: Kimberly M. Jablonski Title: Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR